Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALX-0651
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
ALX-0651 is a biparatopic nanobody (Nb) therapeutic consisting of two monovalent nanobodies targeting different epitopes of the chemokine receptor CXCR4. It was developed by Ablynx, which became a subsidiary of Sanofi. The drug acts as an antagonist of CXCR4, a G protein-coupled receptor involved in hematopoietic stem cell trafficking and implicated in cancer progression and metastasis. Preclinical data suggested that ALX-0651 could block CXCR4-mediated viral entry and induce rapid stem-cell mobilization. It was the first nanobody to enter clinical trials targeting a GPCR, with initial development focused on oncology indications such as non-Hodgkin's lymphoma and multiple myeloma. Clinical development reached phase I but has since been discontinued[1][2][3][5][8].
- Other names
- anti-CXCR4 Nanobodyanti-CXCR-4 Nanobodyanti-CXCR 4 Nanobody
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on ALX-0651.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALX-0651.